"The acquisition of HyperBranch supports our growth strategy within our Neurotechnology business," said
As a PMA approved and CE cleared hydrogel that is indicated for use as an adjunct to standard methods of dural repair to aid in creating a watertight closure of the dura, the Adherus product is highly complementary to Stryker's Craniomaxillofacial division. The patent protected sealant formulation, combined with a differentiated delivery system, is proven through clinical trials to provide clinically safe and effective dural closure.
The transaction is expected to have an immaterial impact to net earnings in 2018.
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Such risk and uncertainties include, but are not limited to: unexpected charges or expenses in connection with the acquisition of HyperBranch; weakening of economic conditions that could adversely affect the level of demand for HyperBranch's products or our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for HyperBranch's products or our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.
For investor inquiries please contact:
For media inquiries please contact:
This announcement is distributed by
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Vice President, Strategy & Investor Relations
2825 Airview Boulevard
Kalamazoo, MI 49002